Intra Cellular Therapies reported $0 in Loan Capital for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Loan Capital Change
Acadia Pharmaceuticals ACAD:US $ 0M 0M
ALKERMES ALKS:US 291.54M 634K
Aptinyx Inc APTX:US $ 24.5M 206K
Biogen BIIB:US $ 6277.4M 1.7M
Bristol Myers Squibb BMY:US $ 37107M 343M
Cytokinetics CYTK:US $ 198.42M 1.34M
Esperion Therapeutics ESPR:US $ 259.08M 402K
Halozyme Therapeutics HALO:US $ 1147.13M 359.03M
Intra Cellular Therapies ITCI:US $ 0M 0M
JAZZ PHA JAZZ:US $ 5990M 2.87M
Marinus Pharmaceuticals MRNS:US $ 70.35M 0.42M
Nektar Therapeutics NKTR:US $ 0M 0M
Neurocrine Biosciences NBIX:US $ 169M 208.7M
Novartis NVS:US $ 23784M 589M
Prothena PRTA:US 0 0
Redhill Biopharma RDHL:US $ 93.58M 7.39M
Supernus Pharmaceuticals SUPN:US $ 0M 400.38M
United Therapeutics UTHR:US $ 800M 0M